Diabetes Rx May Do Double-Duty for Parkinson’s Disease
Sometimes important scientific discoveries occur secondhand. For Parkinson's disease, that may be exactly the case.
Popular Diabetes Rx May Not Cut Bladder Cancer Risk
Widely given to patients with type 2 diabetes, metformin has been linked to reducing the risk for many types of cancers. The medication, however, may not be effective against one certain cancer.
Diabetes Medications May Impact Cancer Risks
People with type 2 diabetes have higher cancer risks than the general population. The link may have to do with how diabetes affects the metabolism. Diabetes medications may also figure into the equation.
Trends in Treating Diabetes
Diabetes is a big problem in the US — and thus, it is a big focus of doctors, researchers and pharmaceutical companies alike. New medications and developments alter how diabetes is treated.
New Diabetes Rx Delivers Results
While several medications are already on the market to treat diabetes, not all patients have the desired control over their blood sugar levels. Alogliptin may offer a fresh option.
Diabetes Drugs Cut Colon Cancer Risk
There are many factors to think about when prescribing drugs to diabetes patients. One of these factors is the cancer risk of a particular drug; or in some cases, the cancer-preventing powers of that drug.
Diabetes Drugs With Highest Bladder Cancer Risks
If you have diabetes, you’ve heard the news about bladder cancer risks and a popular medicine. A new study shows that some common diabetes drugs don’t have the same cancer risks.
Generic Actos to Treat Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) today approved the first generic version of Actos ( pioglitazone hydrochloride) tablets. Along with diet and exercise, pioglitazone is used to improve blood glucose control in adults with type 2 diabetes.
More Studies Find Bladder Cancer Risk
People with type 2 diabetes have an elevated risk of several types of cancer, including liver and pancreatic cancer. The use of one diabetic medication increases the risk of another form of cancer.
Byetta Approved for Use With Basal Insulin
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company BYETTA ( exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos ( pioglitazone ), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.